US Food and Drug Administration (FDA) Approves First RSV Vaccine for Older Adults

Daily Current Affairs / US Food and Drug Administration (FDA) Approves First RSV Vaccine for Older Adults

Change Language English Hindi

Category : International Published on: May 06 2023

Share on facebook

The US Food and Drug Administration (FDA) has approved the first vaccine for respiratory syncytial virus (RSV) in the United States.
‘Arexvy’, manufactured by GSK, is the world's first RSVvaccine for adults aged 60 years and older.
The vaccine was approved for people aged 60 and older after it was found 83 percent effective against diseases caused by RSV and more than 94 percent effective against severe diseases.
RSV causes a lower respiratory illness that is typically mild for healthy adults. But in serious cases, the virus can lead to pneumonia or bronchiolitis, which inflames airways and clogs them with mucus.
According to the US Centers for Disease Control and Prevention, it leads to approximately 60,000 to 120,000 hospitalizations and 6,000 to 10,000 deaths among adults 65 years of age and older.